Randy Bull Email and Phone Number

Business Unit responsibility for multi-business division that includes Skin Care and Medical Devices, with SBU responsibility for Biofunctional Ingredients, Preservatives and Encapsulation platforms. Reporting to Group VP. Total business responsibility ~$300 million.+ Developed acquisitive growth strategy for Personal Care business (one deal complete, one in progress, one unsuccessful)+ Developed and successfully implemented strategy to maintain overall market share in Preservatives segment while several key products declined due to regulatory changes+ Implemented plans that realized >20%/yr new business in each of Biofunctional ingredient and Encapsulation segments+ Expanded scope for medical device business and began securing step change business growth opportunities+ Implemented orderly exit plan for Fine Chemicals business not core to Ashland that resulted in accelerated earnings in near term.

Via acquisition of ISP by Ashland. Key team integration role following acquisition. Led New Product innovation process to refocus innovation toward post acquisition new product introduction targets.

Responsible for Pharmaceutial and Nutrition/Beverage business unit with sales >$400 million. Reporting to CEO.+ Established R&D innovation portfolio that ultimately led (under Ashland) to launch of new ingredient for bioavailabilty enhancement in pharmaceutical solid dose applications+ Won new business in Beverage segment by focused technical support at key customer that improved customer efficiencies

Global sales operations for >$100 million pharmaceutical ingredients and services business. Responsible for key region sales and technical services organization of ~80 people. Reporting to VP/GM.+ Redesigned commercial organization to clarify and differentiate roles of sales, marketing, and technical service+ Established dedicated marketing department to support regional sales organization+ Successful strategy to establish regional technical service laboratories in key growth markets (e.g. China, India) that accelerated growth as customers increased their reliance on Evonik technical capabilities+ Integrated several division product lines into global commercial organization, helping solidify the company's credible business position in pharmaceutical ingredient industry+ Implemented expanded services business model to realize near term bottom line profit in long sales cycle market. (led to new business model and consequent acquisition) and decrease risk in project acquisition